Muscle wasting as main evidence of energy impairment in cancer cachexia: Future therapeutic approaches

Future Oncology

Volumn 11, Issue 19, 2015, Pages 2697-2710

  Madeddu, Clelia ^a   Mantovani, Giovanni ^a   Gramignano, Giulia ^b   Astara, Giorgio ^a   Macciò, Antonio ^c  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b NS Bonaria Hospital   (Italy)

^c Ospedale Oncologico A Businco   (Italy)

Author keywords

advanced cancer; cachexia; IL 6; inflammation; mTOR; muscle wasting; quality of life

Indexed keywords

ANABOLIC AGENT; ANTIINFLAMMATORY AGENT; APPETITE STIMULANT; MONOCLONAL ANTIBODY;

CACHEXIA; CANCER CELL; CLINICAL FEATURE; DISEASE ASSOCIATION; ENERGY METABOLISM; ENERGY RESOURCE; FUTUROLOGY; HUMAN; INFLAMMATION; MUSCLE ATROPHY; MUSCLE STRENGTH; NEOPLASM; NONHUMAN; NUTRITIONAL SUPPORT; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHARMACEUTICAL CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STRESS; TUMOR MICROENVIRONMENT;

EID: 84943805694     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.195     Document Type: Review

References (108)

1. Tsai S. Importance of lean body mass in the oncologic patient. Nutr. Clin. Pract. 27, 593-598 (2012
2. Fearon K, Strasser F, Anker SD., et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12, 489-495 (2011
3. Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. J. Cachexia Sarcopenia Muscle 5, 253-259 (2014
4. Gonzalez MC, Pastore CA, Orlandi SP, Heymsfield SB. Obesity paradox in cancer: new insights provided by body composition. Am. J. Clin. Nutr. 99, 999-1005 (2014
5. Prado CM, Lieffers JR, McCargar LJ., et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 9, 629-635 (2008
6. Martin L, Birdsell L, Macdonald N., et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31, 1539-1547 (2013
7. van der Meij BS, Schoonbeek CP, Smit EF, Muscaritoli M, van Leeuwen PA, Langius JA. Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks. Br. J. Nutr. 109, 2231-2239 (2013
8. Sarhill N, Mahmoud F, Walsh D., et al. Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer 11, 652-659 (2003
9. Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am. J. Clin. Nutr. 91, S1133-S1137 (2010
10. Vigano A, Bruera E, Jhangri GS, Newman SC, Fields AL, Suarez-Almazor ME. Clinical survival predictors in patients with advanced cancer. Arch. Intern. Med. 160, 861-868 (2000
11. Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest. 123, 3685-3692 (2013
12. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2, 881-898 (2012
13. Vander Heiden MG, Lunt SY, Dayton TL., et al. Metabolic pathway alterations that support cell proliferation. Cold Spring Harb. Symp. Quant. Biol. 76, 325-334 (2011
14. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell. Dev. Biol. 27, 441-464 (2011
15. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009
16. Warburg O. On the origin of cancer cells. Science 123, 309-314 (1956
17. Czernin J, Allen-Auerbach M, Nathanson D, Herrmann K. PET/CT in oncology: current status and perspectives. Curr. Radiol. Rep. 1, 177-190 (2013
18. Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer 14, 754-762 (2014
19. Lundholm K, Edström S, Karlberg I, Ekman L, Scherstén T. Glucose turnover, gluconeogenesis from glycerol, and estimation of net glucose cycling in cancer patients. Cancer 50, 1142-1150 (1982
20. Wu J, Huang C, Xiao H, Tang Q, Cai W. Weight loss and resting energy expenditure in male patients with newly diagnosed esophageal cancer. Nutrition 29, 1310-1314 (2013
21. Leij-Halfwerk S, Dagnelie PC, van Den Berg JW, Wattimena JD, Hordijk-Luijk CH, Wilson JP. Weight loss and elevated gluconeogenesis from alanine in lung cancer patients. Am. J. Clin. Nutr. 71, 583-589 (2000
22. Narsale AA, Enos RT, Puppa MJ., et al. Liver inflammation and metabolic signaling in ApcMin/+ mice: the role of cachexia progression. PLoS ONE 10(3), e0119888 (2015
23. Asp ML, Tian M, Wendel AA, Belury MA. Evidence for the contribution of insulin resistence to the development of cachexia in tumor-bearing mice. Int. J. Cancer 126, 756-763 (2010
24. Guasconi V, Puri PL. Epigenetic drugs in the treatment of skeletal muscle atrophy. Curr. Opin. Clin. Nutr. Metab. Care 11, 233-241 (2008
25. Melville S, McNurlan MA, Calder AG, Garlick PJ. Increased protein turnover despite normal energy metabolism and responses to feeding in patients with lung cancer. Cancer Res. 50, 1125-1131 (1990
26. Penna F, Bonetto A, Muscaritoli M., et al. Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved? Int. J. Cancer 127, 1706-1717 (2010
27. MacDonald AJ, Johns N, Stephens N., et al. Habitual myofibrillar protein synthesis is normal in patients with upper GI cancer cachexia. Clin. Cancer Res. 21, 1734-1740 (2015
28. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21-35 (2011
29. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 13, 1016-1023 (2011
30. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424-430 (2006
31. Testa JR, Tsichlis PN. AKT signaling in normal and malignant cells. Oncogene 24, 7391-7393 (2005
32. Salminen A, Kaarniranta K. Insulin/IGF-1 paradox of aging: regulation via AKT/IKK/ NF-kappaB signaling. Cell Signal. 22, 573-577 (2010
33. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 12, 9-22 (2007
34. Polak P, Hall MN. mTOR and the control of whole body metabolism. Curr. Opin. Cell Biol. 21, 209-218 (2009
35. Peng T, Golub TR, Sabatini DM. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol. Cell Biol. 22, 5575-5584 (2002
36. Düvel K, Yecies JL, Menon S., et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39, 171-183 (2010
37. Huang K, Fingar DC. Growing knowledge of the mTOR signaling network. Semin. Cell Dev. Biol. 36C, 79-90 (2014
38. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 149, 274-293 (2012
39. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-Activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 1, 15-25 (2005
40. Inoki K1, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577-590 (2003
41. Op den Kamp CM, Langen RC, Snepvangers FJ., et al. Nuclear transcription factor kB activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. Am. J. Clin. Nutr. 98, 738-748 (2013
42. Remels AH, Gosker HR, Verhees KJ, Langen RC, Schols AM. TNF-α-induced NF-kB Activation Stimulates Skeletal Muscle Glycolytic Metabolism Through Activation of HIF-1α. Endocrinology 156, 1770-1781 (2015
43. Niemi H, Honkonen K, Korpisalo P., et al. HIF-1α and HIF-2α induce angiogenesis and improve muscle energy recovery. Eur. J. Clin. Invest. 44, 989-999 (2014
44. Slot IG, Schols AM, Vosse BA, Kelders MC, Gosker HR. Hypoxia differentially regulates muscle oxidative fiber type and metabolism in a HIF-1α-dependent manner. Cell Signal. 26, 1837-1845 (2014
45. Evans WJ, Morley JE, Argilés J., et al. Cachexia: a new definition. Clin. Nutr. 27, 793-739 (2008
46. Di Sebastiano KM, Yang L, Zbuk K., et al. Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: the relationship with diabetes and anaemia. Br. J. Nutr. 109, 302-312 (2013
47. Hagler L, Askew EW, Neville JR, Mellick PW, Coppes RI Jr, Lowder JF Jr. Influence of dietary iron deficiency on hemoglobin, myoglobin, their respective reductases, and skeletal muscle mitochondrial respiration. Am. J. Clin. Nutr. 34, 2169-2177 (1981
48. Krishnamurthy P, Xie T, Schuetz JD. The role of transporters in cellular heme and porphyrin homeostasis. Pharmacol. Ther. 114, 345-358 (2007
49. Bower JE. Cancer-related fatigue - mechanisms, risk factors, and treatments. Nat. Rev. Clin. Oncol. 11, 597-609 (2014
50. Shirwany NA, Zou MH. AMPK: a cellular metabolic and redox sensor A minireview. Front. Biosci. (Landmark Ed) 19, 447-474 (2014
51. Jones RG, Plas DR, Kubek S., et al. AMP-Activated protein kinase induces a p53- dependent metabolic checkpoint. Mol. Cell. 18, 283-293 (2005
52. Liang J, Shao SH, Xu ZX., et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat. Cell Biol. 9, 218-224 (2007
53. Tong JF, Yan X, Zhu MJ, Du M. AMP-Activated protein kinase enhances the expression of muscle-specific ubiquitin ligases despite its activation of IGF-1/Akt signaling in C2C12 myotubes. J. Cell Biochem. 108, 458-468 (2009
54. Macció A, Madeddu C. Inflammation and ovarian cancer. Cytokine 58, 133-147 (2012
55. Trujillo ME, Sullivan S, Harten I, Schneider SH, Greenberg AS, Fried SK. Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J. Clin. Endocrinol. Metab. 89, 5577-5582 (2004
56. Tisdale MJ. Mechanisms of cancer cachexia. Physiol. Rev. 89, 381-410 (2009
57. Zhong Z, Wen Z, Darnell JE. Stat3: A STAT Family Member Activated by Tyrosine Phosphorylation in Response to Epidermal Growth Factor and interleukin-6. Science 264, 95-98 (1994
58. Demaria M, Giorgi C, Lebiedzinska M., et al A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging 2, 823-842 (2010
59. Banerjee A, Guttridge DC. Mechanisms for maintaining muscle. Curr. Opin. Support Palliat. Care 6, 451-456 (2012
60. Carson JA, Baltgalvis KA. Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc. Sport Sci. Rev. 38, 168-176 (2010
61. Bonetto A, Aydogdu T, Jin X., et al. JAK/ STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 in experimental cancer cachexia. Am. J. Physiol. Endocrinol. Metab. 303, E410-E421 (2012
62. Goodman MN. Interleukin-6 induces skeletal muscle protein breakdown in rats. Proc. Soc. Exp. Biol. Med. 205, 182-185 (1994
63. Tsujinaka T, Fujita J, Ebisui C., et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J. Clin. Invest. 97, 244-249 (1996
64. Muñoz-CA&Acute;noves P, Scheele C, Pedersen BK, Serrano AL. Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword? FEBS J. 280, 4131-4148 (2013
65. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 121, 3375-3383 (2011
66. Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L. Interleukin-6-Type cytokine signalling through the gp130/Jak/ STAT pathway. Biochem. J. 334 (Pt 2), 297-314 (1998
67. Yamamoto T, Sekine Y, Kashima K., et al. The nuclear isoform of protein-Tyrosine phosphatase TC-PTP regulates interleukin- 6-mediated signaling pathway through STAT3 dephosphorylation. Biochem. Biophys. Res. Commun. 297, 811-817 (2002
68. Penna F, Costamagna D, Fanzani A, Bonelli G, Baccino FM, Costelli P. Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS ONE 5, e13604 (2010
69. Glass DJ. Signaling pathways perturbing muscle mass. Curr. Opin. Clin. Nutr. Metab. Care 13, 225-229 (2010
70. Lundholm K, Edström S, Ekman L, Karlberg I, Scherstén T. Metabolism in peripheral tissues in cancer patients. Cancer Treat. Rep. 65(Suppl 5), 79-83 (1981
71. Nemet D, Eliakim A, Zaldivar F, Cooper DM. Effect of rhIL-6 infusion on GH?IGF-I axis mediators in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291 (6), R1663-R1668 (2006
72. White JP, Puppa MJ, Gao S, Sato S, Welle SL, Carson JA. Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK. Am. J. Physiol. Endocrinol. Metab. 304, E1042-E1052 (2013
73. White JP, Baynes JW, Welle SL., et al. The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse. PLoS ONE 6, e24650 (2011
74. Puppa MJ, White JP, VelA&Acute;zquez KT., et al. The effect of exercise on IL-6-induced cachexia in the Apc( Min/+) mouse. J. Cachexia Sarcopenia Muscle 3, 117-137 (2012
75. Roberts BM, Frye GS, Ahn B, Ferreira LF, Judge AR. Cancer cachexia decreases specific force and accelerates fatigue in limb muscle. Biochem. Biophys. Res. Commun. 435, 488-492 (2013
76. Prado CM, Antoun S, Sawyer MB, Baracos VE. Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity. Curr. Opin. Clin. Nutr. Metab. Care 14, 250-254 (2011
77. Stone P, Richards M, AHern R, Hardy J A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann. Oncol. 11, 561-567 (2000
78. Kilgour RD, Vigano A, Trutschnigg B., et al. Cancer-related fatigue: the impact of skeletal muscle mass and strength in patients with advanced cancer. J. Cachexia Sarcopenia Muscle 1, 177-185 (2010
79. Dimeo FC, Stieglitz RD, Novelli-Fischer U, Fetscher S, Keul J. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer 85, 2273-2277 (1999
80. Dimeo F, Schwartz S, Wesel N, Voigt A, Thiel E. Effects of an endurance and resistance exercise program on persistent cancer-related fatigue after treatment. Ann. Oncol. 19, 1495-1499 (2008
81. Convertino VA, Bloomfield SA, Greenleaf JE. An overview of the issues: physiological effects of bed rest and restricted physical activity. Med. Sci. Sports Exerc. 29, 187-190 (1997
82. Payne C, Wiffen PJ, Martin S. Interventions for fatigue and weight loss in adults with advanced progressive illness. Cochrane Database Syst. Rev. 1, CD008427 (2012
83. Lundholm K, Daneryd P, Körner U, Hyltander A, Bosaeus I. Evidence that long-Term COX-Treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int. J. Oncol. 24, 505-512 (2004
84. Lundholm K, Gelin J, Hyltander A., et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res. 54, 5602-5606 (1994
85. Mantovani G, Macciò A, Madeddu C., et al. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J. Mol. Med. (Berl) 88, 85-92 (2010
86. Reid J, Hughes CM, Murray LJ, Parsons C, Cantwell MM. Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review. Palliat. Med. 27, 295-303 (2013
87. Ando K, Takahashi F, Kato M., et al. Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer. PLoS ONE 9, e102436 (2014
88. Ohe Y, Podack ER, Olsen KJ., et al. Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngeneic mice. Br. J. Cancer 67, 939-944 (1993
89. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin. Biol. Ther. 11, 1663-1668 (2011
90. Ando K, Takahashi F, Motojima S., et al. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J. Clin. Oncol. 31, e69-e72 (2013
91. Hirata H, Tetsumoto S, Kijima T., et al. Favorable responses to tocilizumab in two patients with cancer-related cachexia. J. Pain Symptom Manage. 46, e9-e13 (2013
92. Mesa RA, Verstovsek S, Gupta V., et al. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. Clin. Lymphoma Myeloma Leuk. 15, 214-221 (2015
93. Porporato PE, Filigheddu N, Reano S., et al. Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. J. Clin. Invest. 123, 611-622 (2013
94. Sugiyama M, Yamaki A, Furuya M., et al. Ghrelin improves body weight loss and skeletal muscle catabolism associated with angiotensin II-induced cachexia in mice. Regul. Pept. 178, 21-28 (2012
95. Tsubouchi H, Yanagi S, Miura A, Matsumoto N, Kangawa K, Nakazato M. Ghrelin relieves cancer cachexia associated with the development of lung adenocarcinoma in mice. Eur. J. Pharmacol. 743, 1-10 (2014
96. Temel J, Bondarde S, Jain M., et al. Efficacy and safety results from a Phase II study of anamorelin HCl, a ghrelin receptor agonist, in NSCLC patients. J. Cachexia Sarcopenia Muscle 4, 295-343 (2013
97. Temel JS, Currow DC, Fearon K, Yan Y Friend J Abernethy AP , Phase III trials of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia (ROMANA 1 and 2). J. Clin. Oncol. 33(Suppl), Abstract 9500 (2015
98. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat. Rev. Clin. Oncol. 10, 90-99 (2013
99. Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J. Cachexia Sarcopenia Muscle 1, 9-21 (2010
100. Narsale AA, Carson JA. Role of interleukin-6 in cachexia: therapeutic implications. Curr. Opin. Support. Palliat. Care 8, 321-327 (2014
101. Stene GB, Helbostad JL, Balstad TR, Riphagen II, Kaasa S, Oldervoll LM. Effect of physical exercise on muscle mass and strength in cancer patients during treatment - A systematic review Crit. Rev. Oncol. Hematol. 88, 573-593 (2013
102. Oldervoll LM, Loge JH, Lydersen S., et al. Physical exercise for cancer patients with advanced disease: a randomized controlled trial. Oncologist 16, 1649-1657 (2011
103. Grande AJ, Silva V, Riera R., et al. Exercise for cancer cachexia in adults. Cochrane Database Syst. Rev. 11, CD010804 (2014
104. Nixon DW, Lawson DH, Kutner M., et al. Hyperalimentation of the cancer patient with protein-calorie undernutrition. Cancer Res. 41, 2038-2045 (1981
105. Muscaritoli M, Costelli P, Aversa Z, Bonetto A, Baccino FM, Rossi Fanelli F. New Strategies to Overcome Cancer Cachexia: From Molecular Mechanisms to the Parallel Pathway. Asia Pac J Clin Nutr. 17(Suppl 1), 387-390 (2008
106. Aversa Z, Bonetto A, Costelli P., et al. β-hydroxy-β-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia. Int. J. Oncol. 38, 713-720 (2011
107. Smith GI, Atherton P, Reeds DN., et al. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial. Am J. Clin. Nutr. 93, 402-412 (2011
108. Macciò A, Madeddu C, Gramignano G., et al A randomized Phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol. Oncol. 124, 417-425 (2012